KUALA LUMPUR, Malaysia--(BUSINESS WIRE)--IndiPharm (M) SDN BHD, a division of IndiPharm Inc. was awarded BioNexus status from the Malaysian Biotechnology Corporation (Biotechcorp) at BIO Philadelphia 2015, held on June 15-18, 2015.
IndiPharm is a Clinical Development Organization, headquartered in the United States, with clinical and administrative operations in Malaysia and India. IndiPharm’s experienced management team, U.S.-based client services, strong global SOPs, well-trained medical professional staff, and deep understanding of local culture and regulatory systems, facilitates the delivery of high-quality clinical trials with lower costs, faster recruitment, and better quality outcomes.
Biotechcorp is an agency under the purview of Ministry of Science, Technology and Innovation (MOSTI), and is owned by the Ministry of Finance Incorporated & Federal Lands Commissioner. It is governed by the National Bioeconomy Council and advised by the Biotechnology International Advisory Panel, both chaired by the Honorable Prime Minister of Malaysia. Biotechcorp is responsible for executing the objectives of the National Biotechnology Policy (NBP) by identifying value propositions in both R&D and commerce, and supporting these ventures via financial assistance and developmental services.
BioNexus is a special status awarded to qualified international and Malaysian companies undertaking value-added biotechnology and/or life sciences activities. The status endows fiscal incentives, grants, and other guarantees to assist growth.
Dato’ Dr. Mohd. Nazlee Kamal, Chief Executive Officer of Malaysian Biotechnology Corporation said, “We are very pleased for IndiPharm to join the list of BioNexus status companies, especially as they have chosen to establish their Asian headquarters in Malaysia. IndiPharm’s vast knowledge and expertise in clinical research services will undoubtedly enrich the growth of the biomedical sector in Malaysia, particularly in conducting clinical trials. We hope IndiPharm will take full advantage of the benefits that the BioNexus status offers to contribute to the healthcare community.”
IndiPharm Inc. has relocated its Asian operations center to Kuala Lumpur in anticipation of future growth and client demands. Edward Brennan MD, President and CEO of IndiPharm Inc. stated, “IndiPharm is excited to have received the BioNexus status. Aside from the financial incentives provided, the Bionexus status grants IndiPharm access to clients and markets that otherwise would not be possible. We look forward to a long and successful relationship with Malaysian Biotechnology Corporation as we continue to expand our presence in Malaysia and Asia.”